IRIS UniCatt

Pane, Marika
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.114
AS - Asia 9.370
EU - Europa 8.701
SA - Sud America 1.772
AF - Africa 256
OC - Oceania 21
Continente sconosciuto - Info sul continente non disponibili 6
Totale 30.240
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.707
SG - Singapore 4.483
DE - Germania 2.149
CN - Cina 2.038
IT - Italia 1.947
BR - Brasile 1.448
SE - Svezia 887
NL - Olanda 854
VN - Vietnam 820
FR - Francia 769
GB - Regno Unito 420
IE - Irlanda 391
IN - India 323
JP - Giappone 278
ID - Indonesia 272
HK - Hong Kong 241
FI - Finlandia 230
UA - Ucraina 222
RU - Federazione Russa 219
CA - Canada 201
BD - Bangladesh 181
PL - Polonia 145
KR - Corea 137
AR - Argentina 131
MX - Messico 124
TR - Turchia 120
IQ - Iraq 97
ES - Italia 92
ZA - Sudafrica 78
AT - Austria 65
PK - Pakistan 54
EC - Ecuador 50
BE - Belgio 47
CH - Svizzera 42
SA - Arabia Saudita 39
IR - Iran 38
CZ - Repubblica Ceca 37
LT - Lituania 36
VE - Venezuela 33
CO - Colombia 31
AE - Emirati Arabi Uniti 27
MA - Marocco 27
UZ - Uzbekistan 27
CI - Costa d'Avorio 26
EG - Egitto 26
PH - Filippine 25
KE - Kenya 24
PA - Panama 23
CL - Cile 22
IL - Israele 22
JO - Giordania 22
PY - Paraguay 21
RO - Romania 19
TN - Tunisia 18
RS - Serbia 17
OM - Oman 15
PE - Perù 14
BG - Bulgaria 13
MK - Macedonia 13
UY - Uruguay 13
KZ - Kazakistan 12
AU - Australia 11
CR - Costa Rica 11
DZ - Algeria 11
NP - Nepal 11
AZ - Azerbaigian 10
DO - Repubblica Dominicana 10
NG - Nigeria 10
PT - Portogallo 10
AL - Albania 9
DK - Danimarca 9
MY - Malesia 9
BY - Bielorussia 8
KG - Kirghizistan 8
NZ - Nuova Zelanda 8
SK - Slovacchia (Repubblica Slovacca) 8
HU - Ungheria 7
TH - Thailandia 7
TT - Trinidad e Tobago 7
TW - Taiwan 7
AM - Armenia 6
BO - Bolivia 6
ET - Etiopia 6
GR - Grecia 6
HR - Croazia 6
JM - Giamaica 6
LK - Sri Lanka 6
SN - Senegal 6
GE - Georgia 5
HN - Honduras 5
LB - Libano 5
LV - Lettonia 5
NI - Nicaragua 5
BH - Bahrain 4
GT - Guatemala 4
SY - Repubblica araba siriana 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AO - Angola 3
EE - Estonia 3
GA - Gabon 3
Totale 30.170
Salva come PNG Salva come JPEG
Città #
Singapore 2.665
San Jose 1.250
Ashburn 1.187
Chandler 1.008
Amsterdam 713
New York 447
Hefei 390
Rome 376
Dublin 357
Beijing 355
Los Angeles 319
Ho Chi Minh City 293
Frankfurt am Main 269
Milan 267
Tokyo 260
Jakarta 248
Lauterbourg 235
Hong Kong 216
Hanoi 198
Munich 178
Dallas 174
São Paulo 155
San Mateo 150
Boston 134
Seoul 132
Tukwila 126
Chicago 124
Moscow 123
Jacksonville 122
Helsinki 113
Marseille 111
Kent 110
Nanjing 100
Warsaw 98
Santa Clara 96
Wilmington 96
Buffalo 94
Houston 94
Nürnberg 91
The Dalles 91
Boardman 79
Dearborn 79
Princeton 78
Orem 75
London 71
Ann Arbor 70
Atlanta 70
Montreal 70
Nuremberg 70
Woodbridge 67
Brooklyn 65
Council Bluffs 65
Paris 62
Seattle 62
Chennai 59
Denver 57
Stockholm 54
Johannesburg 52
Toronto 50
Bremen 49
Mexico City 49
Da Nang 48
Poplar 48
Phoenix 45
Baghdad 44
Düsseldorf 44
Fairfield 44
Nanchang 42
Brussels 39
Shanghai 38
Lappeenranta 37
Palermo 37
Pune 37
Rio de Janeiro 37
San Francisco 37
Belo Horizonte 36
Redwood City 33
Ankara 32
Turku 32
Augusta 31
Brasília 31
Lawrence 31
Haiphong 29
Vienna 29
Hebei 27
Abidjan 26
Bologna 26
Brno 26
Falkenstein 26
Lancaster 26
Mumbai 26
Tianjin 26
Biên Hòa 25
Detroit 25
New Delhi 25
Turin 25
Cattolica 24
City of London 24
Dhaka 24
Florence 24
Totale 16.184
Salva come PNG Salva come JPEG
Nome #
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 959
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 503
Validation and cross-cultural adaptation of the Italian version of the Pediatric Eating Assessment Tool (I-PEDI-EAT-10) in genetic syndromes 396
Oral and Swallowing Abilities Tool (OrSAT) for Type 1 SMA Patients: Development of a New Module 335
Reliability of the Performance of Upper Limb assessment in Duchenne muscular dystrophy 311
Cortical visual function in preterm infants in the first year. 276
Neurological examination of preterm infants a term equivalent age 271
Performance of Upper Limb module for Duchenne muscular dystrophy 237
Prognostic value of EEG performed at term age in preterm infants. 230
Neurological examination at 6 to 9 months in infants with cystic periventricular leukomalacia 225
Assessing floppy infants: a new module 212
-Thalamic atrophy in infants with PVL and cerebral visual impairment 205
Oral and Swallowing Abilities Tool (OrSAT) in nusinersen treated patients 202
Crossed cerebellar atrophy of prenatal onset 202
Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening 191
Developmental milestones in type I spinal muscular atrophy 189
Co-occurrence of fragile x syndrome with a second genetic condition: Three independent cases of double diagnosis 184
A current approach to heart failure in Duchenne muscular dystrophy 183
Salbutamol increases survival motor neuron (SMN) transcript levels in leucocytes of spinal muscular atrophy (SMA) patients: relevance for clinical trial design. 181
Visual development in prenatal post-haemorragic ventricular dilatation 180
SMN transcript levels in leukocytes of SMA patients determined by absolute real-time PCR. 179
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 179
Experience of a 2-year spinal muscular atrophy NBS pilot study in Italy: towards specific guidelines and standard operating procedures for the molecular diagnosis 178
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 172
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 169
Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study 166
Cardiac Function in Types II and III Spinal Muscular Atrophy: Should We Change Standards of Care? 166
Body mass index in type 2 spinal muscular atrophy: a longitudinal study 165
Attention Deficit Hyperactivity Disorder and Cognitive Function in Duchenne Muscular Dystrophy: Phenotype-Genotype Correlation 165
Type I SMA “new natural history”: long-term data in nusinersen-treated patients 165
Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naïve patients with spinal muscular atrophy and following switch from other therapies 164
SMA-miRs (MiR-181a- 5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples 164
Muscle MRI in Becker muscular dystrophy 163
Muscle MRI in Becker muscular dystrophy 162
SMA-miRs (MiR-181a- 5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples 161
Early neurological signs in infants identified through neonatal screening for SMA: do they predict outcome? 160
Muscle MRI: Out of the tunnel. 159
Different trajectories in upper limb and gross motor function in spinal muscular atrophy 157
Gain and loss of upper limb abilities in Duchenne muscular dystrophy patients: A 24-month study 156
Longitudinal evaluation of SMN levels as biomarker for spinal muscular atrophy: results of a phase IIb double-blind study of salbutamol 156
Cardiac Function in Types II and III Spinal Muscular Atrophy: Should We Change Standars of Care? 155
Nusinersen in type 1 spinal muscular atrophy: Twelve-month real-world data 154
Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen 154
Expanded access program with Nusinersen in SMA type I in Italy: Strengths and pitfalls of a successful experience 153
Co-occurrence of fragile x syndrome with a second genetic condition: Three independent cases of double diagnosis 153
Contactless: a new personalised telehealth model in chronic pediatric diseases and disability during the COVID-19 era 152
A critical review of functional assessment tools for upper limbs in Duchenne muscular dystrophy 151
Respiratory function and therapeutic expectations in DMD: Families experience and perspective 151
Experience of a 2-year spinal muscular atrophy NBS pilot study in Italy: Towards specific guidelines and standard operating procedures for the molecular diagnosis 150
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen 150
Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy 149
Predominant distal muscle involvement in spinal muscular atrophy 148
The nonsense mutation stop+4 model correlates with motor changes in Duchenne muscular dystrophy 148
Can the CHOP-INTEND be used as An Outcome Measure in the First Months of Age? Implications for Clinical Trials and Real World Data 147
Muscle magnetic resonance imaging involvement in muscular dystrophies with rigidity of the spine 147
Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy 147
Revised upper limb module for spinal muscular atrophy: Development of a new module 146
Disease Trajectories in the Revised Hammersmith Scale in a Cohort of Untreated Patients with Spinal Muscular Atrophy types 2 and 3 145
Upper limb function in Duchenne muscular dystrophy: 24 month longitudinal data. 145
Salbutamol increases serviva motor neuron (SMN) patients: relevance for clinical trial design 144
Congenital muscular dystrophies with defective glycosylation of dystroglycan: a population study 144
Type I Spinal Muscular Atrophy patients treated with nusinersen: 4 year follow-up of motor, respiratory and bulbar function 143
2-Year Change in Revised Hammersmith Scale Scores in a Large Cohort of Untreated Paediatric Type 2 and 3 SMA Participants 142
6MWT can identify type 3 SMA patients with neuromuscular junction dysfunction 142
Longitudinal assessments in discordant twins with SMA 141
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 139
Early Gross Motor Milestones in Duchenne Muscular Dystrophy 139
Congenital muscular dystrophies with cognitive impairment. A population study 138
Expanding the clinical-pathological and genetic spectrum of RYR1-related congenital myopathies with cores and minicores: an Italian population study 138
A Longitudinal Follow-Up Study of Intellectual Function in Duchenne Muscular Dystrophy over Age: Is It Really Stable? 138
Myostatin Levels in SMA Following Disease-Modifying Treatments: A Multi-Center Study 137
24 month longitudinal data in ambulant boys with duchenne muscular dystrophy 137
Longitudinal motor functional outcomes and magnetic resonance imaging patterns of muscle involvement in upper limbs in duchenne muscular dystrophy 137
The Spinal Muscular Atrophy Health Index: Italian validation of a disease-specific outcome measure 136
Ambulatory function in spinal muscular atrophy: Age-related patterns of progression. 135
Type I spinal muscular atrophy and disease modifying treatments: a nationwide study in children born since 2016 135
Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen 134
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 134
Genetic characterization in symptomatic female DMD carriers: lack of relationship between X-inactivation, transcriptional DMD allele balancing and phenotype 134
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial 134
Needleless inhaled anesthesia with sevoflurane: Advantages of a simplified approach for children with spinal muscular atrophy undergoing intrathecal administration of nusinersen 133
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 133
Language Development in Preschool Duchenne Muscular Dystrophy Boys 133
-Electroclinical patterns and evolution of epilepsy in the 4p- syndrome 133
Timed Rise from Floor as a Predictor of Disease Progression in Duchenne Muscular Dystrophy: An Observational Study 133
6 minute walk test in duchenne MD patients with different mutations:12 month changes 133
Revised north star ambulatory assessment for young boys with Duchenne muscular dystrophy 133
Early treatment of type II SMA slows rate of progression of scoliosis 132
MRI: Out of the tunnel. 131
Functional levels and MRI patterns of muscle involvement in upper limbs in Duchenne muscular dystrophy. 131
Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy 131
Prevalence of Duchenne muscular dystrophy in Italy: a nationwide survey 130
Emergencies cards for neuromuscular disorders 1st Consensus Meeting from UILDM - Italian Muscular Dystrophy Association Workshop report 130
Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53 130
Respiratory Trajectories in Type 2 and 3 Spinal Muscular Atrophy in the iSMAC Cohort Study 130
Cost-effectiveness of treatments for presymptomatic newborn patients with spinal muscular atrophy and two or three copies of the survival motor neuron 2 gene in Italy 130
SEPN1-related myopathies: clinical course in a large cohort of patients 129
An observational study of functional abilities in infants, children, and adults with type 1 SMA. 129
Longitudinal Analysis of PUL 2.0 Domains in Ambulant and Non-Ambulant Duchenne Muscular Dystrophy Patients: How do they Change in Relation to Functional Ability? 128
Nusinersen in pediatric and adult patients with type III spinal muscular atrophy 127
Totale 17.343
Salva come PNG Salva come JPEG
Categoria #
all - tutte 127.942
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 127.942
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20215 0 0 0 0 0 0 0 0 0 0 0 5
2021/20221.137 80 37 21 110 80 38 23 192 68 67 208 213
2022/20233.141 302 385 205 465 198 400 221 281 398 60 147 79
2023/20242.651 114 471 102 179 106 410 354 102 52 131 270 360
2024/20255.462 124 100 405 245 458 262 230 242 782 421 1.221 972
2025/202615.426 1.773 538 1.054 1.899 2.791 1.855 2.367 645 758 833 616 297
Totale 30.634